Puma Biotechnology (PBYI) Payables (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Payables came in at $8.2 million in Q1 2026, up 35.51% YoY from $6.0 million in Q1 2025, and up 61.51% on a QoQ basis from $5.1 million in Q4 2025.
Puma Biotechnology (PBYI) Payables (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Payables data on file, last reported at $8.2 million in Q1 2026.
- Quarterly Payables rose 35.51% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 35.51% YoY) and the FY2025 annual result came in at $5.1 million, down 8.22% from the prior year.
- Payables rose to $8.2 million in Q1 2026, from $5.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $14.9 million in Q3 2022 to a low of $5.1 million in Q4 2025.
- A 5-year average of $7.9 million and a median of $7.4 million in 2022 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables tumbled 66.09% — and 2024, when it jumped 73.19%.
- Tracing PBYI's Payables over 5 years: stood at $6.4 million in 2022, then increased by 6.97% to $6.9 million in 2023, then fell by 20.03% to $5.5 million in 2024, then slipped by 8.22% to $5.1 million in 2025, then jumped by 61.51% to $8.2 million in 2026.
- The last three Payables figures came in at $8.2 million (Q1 2026), $5.1 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.11 Mn |
| Mar 31, 2026 | 8.17 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Jun 30, 2025 | 5.42 Mn |
| Mar 31, 2025 | 6.03 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Sep 30, 2024 | 7.51 Mn |
| Jun 30, 2024 | 13.50 Mn |
| Mar 31, 2024 | 8.96 Mn |
| Dec 31, 2023 | 6.89 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 7.80 Mn |
| Mar 31, 2023 | 8.59 Mn |
| Dec 31, 2022 | 6.44 Mn |
| Sep 30, 2022 | 14.93 Mn |
| Jun 30, 2022 | 9.84 Mn |
| Mar 31, 2022 | 7.41 Mn |
| Dec 31, 2021 | 11.17 Mn |
| Sep 30, 2021 | 20.05 Mn |